TY - JOUR
T1 - Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy
AU - Diamantopoulos, Alexander
AU - Benucci, Maurizio
AU - Capri, Stefano
AU - Berger, Wolfgang
AU - Wintfeld, Neil
AU - Giuliani, Giovanni
AU - Ricciardi, Walter
PY - 2012
Y1 - 2012
N2 - This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer's perspective in Italy.
AB - This study was designed to evaluate the cost utility of tocilizumab in rheumatoid arthritis (RA) patients, with inadequate responses to traditional disease-modifying anti-rheumatic drugs (tDMARDs) from a payer's perspective in Italy.
KW - Antibodies, Monoclonal, Humanized
KW - Arthritis, Rheumatoid
KW - Cost-Benefit Analysis
KW - Drug Therapy, Combination
KW - Female
KW - Health Care Costs
KW - Health Resources
KW - Humans
KW - Italy
KW - Male
KW - Quality of Life
KW - Quality-Adjusted Life Years
KW - Severity of Illness Index
KW - Tumor Necrosis Factor-alpha
KW - Antibodies, Monoclonal, Humanized
KW - Arthritis, Rheumatoid
KW - Cost-Benefit Analysis
KW - Drug Therapy, Combination
KW - Female
KW - Health Care Costs
KW - Health Resources
KW - Humans
KW - Italy
KW - Male
KW - Quality of Life
KW - Quality-Adjusted Life Years
KW - Severity of Illness Index
KW - Tumor Necrosis Factor-alpha
UR - http://hdl.handle.net/10807/40265
UR - http://informahealthcare.com/doi/abs/10.3111/13696998.2012.665110
U2 - 10.3111/13696998.2012.665110
DO - 10.3111/13696998.2012.665110
M3 - Article
SN - 1369-6998
VL - 15
SP - 576
EP - 585
JO - Journal of Medical Economics
JF - Journal of Medical Economics
ER -